ArticleAnnals of intensive care2011
Erythropoietin (EPO) in acute kidney injury.
Article in Annals of intensive care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03776851 (Effect of Erythropoietin on Red Blood Cell Requirement in Children With Hemolytic Uremic Syndrome), which is not on this map. Cited by 62 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Erythropoietin on Red Blood Cell Requirement in Children With Hemolytic Uremic Syndrome: a Randomized Controlled Trial
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Erythropoiesis-stimulating agents for preventing acute kidney injury.The Cochrane database of systematic reviews · 2024Pooled it
- Risk Factors for Anemia in Patients with Chronic Renal Failure: A Systematic Review and Meta-Analysis.Ethiopian journal of health sciences · 2020Pooled it
- Erythropoiesis stimulating agents and reno-protection: a meta-analysis.BMC nephrology · 2017Pooled it
- Interventions for protecting renal function in the perioperative period.The Cochrane database of systematic reviews · 2013Pooled it
- The Impact of Erythropoietin on Short- and Long-Term Kidney-Related Outcomes in Neonates of Extremely Low Gestational Age. Results of a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial.The Journal of pediatrics · 2021Trial
- Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety.Critical care (London, England) · 2013Trial
- Trial
- Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study.BMC nephrology · 2012Trial
- Erythropoietin and Ferulic Acid Loaded on FeApplied biochemistry and biotechnology · 2026Article
- Implant Renal Injury-Responsive Cells to Supplement Erythropoietin and Protect Kidney Injury.MedComm · 2025Article
- Case Report: Successful management of acute kidney injury following interventional heartworm extraction in a dog with caval syndrome.Frontiers in veterinary science · 2025Article
- Cardiovascular physiology and pathophysiology at high altitude.Nature reviews. Cardiology · 2024Review
- The impact of hypoxia-inducible factors in the pathogenesis of kidney diseases: a link through cell metabolism.Kidney research and clinical practice · 2023Article
- Suppression of Indoxyl Sulfate Accumulation Reduces Renal Fibrosis in Sulfotransferase 1a1-Deficient Mice.International journal of molecular sciences · 2023Article
- Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Renal hypoxia-HIF-PHD-EPO signaling in transition metal nephrotoxicity: friend or foe?Archives of toxicology · 2022Review
- Mechanisms of cardiovascular toxicity induced by PMEnvironmental science and pollution research international · 2021Review
- Regression Modeling of the Antioxidant-to-Nephroprotective Relation Shows the Pivotal Role of Oxidative Stress in Cisplatin Nephrotoxicity.Antioxidants (Basel, Switzerland) · 2021Article
- Contribution of Oxidative Stress to HIF-1-Mediated Profibrotic Changes during the Kidney Damage.Oxidative medicine and cellular longevity · 2021Review
- The influence of erythropoietin on apoptosis and fibrosis in the early phase of chronic pancreatitis in rats.Archives of medical science : AMS · 2021Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin (EPO) is a 30.4 kDa glycoprotein produced by the kidney, and is mostly well-known for its physiological function in regulating red blood cell production in the bone marrow. Accumulating evidence, however, suggests that EPO has additional organ protective effects, which may be useful in the prevention or treatment of acute kidney injury. These protective mechanisms are multifactorial in nature and include inhibition of apoptotic cell death, stimulation of cellular regeneration, inhibition of deleterious pathways, and promotion of recovery.In this article, we review the physiology of EPO, assess previous work that supports the role of EPO as a general tissue protective agent, and explain the mechanisms by which it may achieve this tissue protective effect. We then focus on experimental and clinical data that suggest that EPO has a kidney protective effect.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.